176 results about "Acute kidney injury" patented technology

The invention relates to a health-care product composite with an alcoholism relieving function and a preparation method thereof, and discloses a health-care product composite with an alcoholism relieving function and a preparation method thereof. The composite is prepared from the following raw materials: pueraria flower, hovenia dulcis thumb, kudzuvine root, green tea and oligosaccharide, wherein plantain herb, chrysanthemum, lalang grass rhizome, liquoric root, tangerine peel and hawthorn fruit are also added into the raw materials of the composite. The health-care product composite is prepared by refining wild plants, does not have toxic or side effect, has excellent effects of relieving alcoholism and activating spleen and protecting liver and stomach, and can eliminate or relieve acute mild and moderate alcoholism, acute stomach injury, chronic gastritis and acute liver injury which are caused by drinking. The health-care product composite can be prepared into granules, tea bags and capsules.

A bifunctional hormone exhibiting an alpha-MSH activity and a natriuretic peptide activity is described. The bifunctional hormone comprises for example a first domain having alpha-MSH related hormonal activity covalently linked to a second domain having natriuretic peptide related hormonal activity. The bifunctional hormone of the present invention is useful for example for the prevention and / or treatment of renal related diseases or conditions, such as acute renal failure (ARF) or acute kidney injury (AKI).

The invention provides a Tibetan capillaris extract, which comprises components of secoiridoid, xanthone, triterpene and the like, wherein the total content of the three components is 20%-80% (by weight). The invention also provides a preparation method of the Tibetan capillaris extract, and a pharmaceutical composition containing the Tibetan capillaris extract. The Tibetan capillaris extract hasthe obvious function of benefiting the cholecyst, and has obvious functions of protecting and improving acute liver injury caused by chemicals and hypohepatia of obstructive jaundice.

It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0 / G1 cell cycle arrest, and / or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0 / G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.

A method for treating a patient suffering from one of septic shock, acute kidney injury, severe hypotension, cardiac arrest, and refractory hypotension, but not from myocardial infarction, is provided. The method includes administering a therapeutically effective dose of Angiotensin II, or Ang II, to the patient.

The present invention provides methods, reagents and kits for diagnosing and / or for the prognosis of non-autoimmune acute joint inflammation by detecting cytokine biomarkers in a sample obtained from an individual thought to be suffering from joint injury. The cytokine biomarkers used with the methods and kits of the present invention are IL-6, MIP-1β, MCP1 and IFNγ.

Systems and methods are provided for predicting the likelihood of acute kidney injury. An input interface is configured to receive a plurality of features derived from the results of a post-surgical metabolic blood panel and either a pre-surgical metabolic blood panel or a perisurgical metabolic blood panel. A predictive model is configured to calculate a parameter representing a likelihood of acute kidney injury from the plurality of features. A user interface is configured to provide the calculated parameter to a user in a human comprehensible form.

Disclosed is a novel biomarker which is useful for the prediction of early onset of acute renal disorder, the estimation of prognosis associated with a renal function, and the diagnosis of acute renal disorder. Also disclosed is use of the novel biomarker. A midkine is used as the biomarker. The determination of the possibility of the onset of acute renal disorder, the estimation of prognosis associated with a renal function or the diagnosis of acute renal disorder can be achieved based on the results of the detection of a midkine in urine.

The invention discloses a molecular marker and kit for early diagnosis and prediction of septicopyemia complicated by acute kidney injury and application thereof. TCONS_00024536 is highly expressed inthe blood of the patient suffering from septicopyemia complicated by acute kidney injury and through detecting the expression level of TCONS_00024536 in the patient blood, septicopyemia complicated by acute kidney injury or the probability of septicopyemia complicated by acute kidney injury are determined. The molecular marker and kit have the great significance for specific and sensitive early diagnosis and prediction of septicopyemia complicated by acute kidney injury.

A method for the early identification and prediction of an abrupt reduction in kidney function in a patient undergoing cardiothoracic (CT) surgery, including Cardio-Pulmonary Bypass (CPB), comprises contacting a urine sample from the patient with a capture molecule for a biomarker, especially πGST, specific for the distal region of the renal tubule and which biomarker is released from said region when there is damage to said region indicative and predictive of an abrupt reduction in kidney function, the biomarker being detectable as early as intraoperatively or in the recovery stage post CT surgery, for example prior to transfer of the patient to the Intensive Care Unit (ICU), allowing for immediate corrective medical intervention. The method can be used to detect Acute Kidney Injury (AKI) and a requirement for Renal Replacement Therapy (RRT) namely dialysis, earlier than two hours post CT surgery and as early as zero hours post or during CT surgery or CPB.

The present invention discloses the application of the mPGES-2 as a target in the treatment or prevention of drug-induced acute liver injury, and belongs to the field of biomedicine. Experiments haveshown that in an acetaminophen-induced mouse acute liver injury model, knockout of the mPGES-2 can significantly reduce ALT and AST levels in the serum, and overexpression of the mPGES-2 can increasethe ALT and AST levels in the serum. This indicates that the mPGES-2 has a regulatory effect on acetaminophen-induced acute liver injury, and the mPGES-2 can be used as a new target for the treatmentor prevention of drug-induced acute liver injury. Knockout of the mPGES-2 can reduce p-JNK and inflammatory responses by inhibiting the oxidative stress, so that acetaminophen-induced acute liver injury can be significantly reduced.

A catheter devices / systems and methods therefrom are described herein for treating acute kidney injury, especially the contrast-induced acute kidney injury wherein the devices prevent the contrast dyes from entering into kidney and / or facilitate blood flow of kidney by said catheter system.

Systems, devices and methods for draining and analyzing bodily fluids and assessing health are described and generally comprise a drainage tube in fluid communication with at least one opening near or at a distal end of a catheter, a pump in fluid communication with the drainage tube and configured to apply a negative pressure to the drainage tube, and a valve configured for unidirectional flow and in fluid communication with the drainage tube. A controller is configured to actuate the pump to apply the negative pressure for clearing an airlock and to monitor a urine output from the patient over a first predetermined period of time above a urine output threshold and over a second predetermined period of time below the urine output threshold. The controller may determine a risk of acute kidney injury if the urine output below the urine output threshold exceeds the second predetermined period of time.